Breast cancer is a common cause of brain metastases and new research has shown that metastatic cells can invade the meninges not by entering the circulation and crossing the blood-brain barrier, but by traveling along the outer surface of the blood vessels that connect the vertebral bone marrow and the skull. Read More
Injectable glucagon-like peptide 1 receptor (GLP-1R) agonists have shown efficacy in weight management and glycemic control. Semaglutide is available as an oral formulation, but it requires specific timing and conditions. Carmot Therapeutics Inc. has presented data for its oral GLP-1R agonist CT-996 from preclinical studies in obesity; the drug is currently in early clinical development. Read More
NLS Pharmaceutics Ltd. has announced preclinical results from in vitro studies targeting α-synuclein, specifically the A53T mutation, demonstrating the potential of Aexon Labs Inc.’s compounds for Parkinson’s disease. Read More
The first development candidate has been nominated under a collaboration between Carisma Therapeutics Inc. and Moderna Inc. to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocytes and macrophages (CAR-M) therapeutics for the treatment of cancer. Read More
Tiger Biotherapeutics Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety coupled to a GTPase KRAS (mutant)-binding moiety through a linker. Read More
Shigella flexneri is the leading cause of endemic diarrhea and dysentery in some countries with low-to-middle incomes. There is still a lack of a licensed vaccine against this pathogen. Read More
Hypoxia, a hallmark of the tumor microenvironment (TME), promotes malignant progression and resistance to chemotherapy and radiotherapy and hence, should be delimitated before treatment initiation. Read More
Takeda Pharmaceutical Co. Ltd. has discovered orexin OX2 receptor agonists reported to be useful for the treatment of narcolepsy, among others. Read More
Microtubules need to maintain a dynamic balance between polymerization and depolymerization to accomplish their role in cell division and other functions. Classical tubulin-targeting agents are divided into microtubule stabilizers and tubulin polymerization inhibitors. Read More
Hainan Simcere Pharmaceutical Co. Ltd. has patented fibroblast growth factor receptor 3 (FGFR3) inhibitors reported to be useful for the treatment of cancer. Read More
Shenyang Pharmaceutical University has identified serine/threonine-protein kinase PLK4 (STK18) inhibitors reported to be useful for the treatment of cancer. Read More
Since heat shock protein 90 (Hsp90) is highly overexpressed in cancer, it is considered both a tumor marker and a therapeutic target for intervention. Read More
